Valneva SE
VALN
查看詳細走勢圖
8.485USD
+0.125+1.50%
收盤 12/24, 13:00（美東）報價延遲15分鐘
1.38B總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
+1.50%
5天
+2.97%
1月
-3.80%
6月
+51.52%
今年開始到現在
+94.08%
1年
+102.51%
查看詳細走勢圖
TradingKey Valneva SE股票評分
單位: USD 更新時間: 2025-12-24操作建議
Valneva SE當前公司基本面數據相對健康，增長潛力較大。當前估值合理，在生物技術與醫療研究行業排名114/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為買入。最高目標價12.89。中期看，股價處於下降通道。近一個月，市場表現較差，但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Valneva SE評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
4
分析師
買入
評級
12.887
目標均價
+44.48%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Valneva SE亮點
亮點風險
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
估值高估
公司最新PE估值-7.66，處於3年歷史高位
機構加倉
最新機構持股4.53M股，環比增加44.31%
活躍度增加
近期活躍度增加，過去20天平均換手率3.26
Valneva SE新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Valneva SE簡介
Valneva SE is a France-based company that specializes in the development, manufacture and commercialization of vaccines to protect people from infectious diseases through preventative medicine. The Company's portfolio includes two commercial vaccines for travelers: IXIARO/JESPECT, for the prevention of Japanese Encephalitis, and DUKORAL, which is indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by Enterotoxigenic escherichia coli (ETEC). The Company has also vaccines in development, including candidates against Lyme disease, COVID-19 and chikungunya. Its technologies and services segment cooperates with various pharmaceutical companies using its platform: EB66 vaccine production cell line and IC31 adjuvant. The Company is focused on research and development (R&D) programs, as well as holds investment in product candidates and commercial products.
公司代碼VALN
公司Valneva SE
CEOLingelbach (Thomas)
網址https://valneva.com/
常見問題
Valneva SE(VALN)的當前股價是多少？
Valneva SE(VALN)的當前股價是 8.485。
Valneva SE 的股票代碼是什麼？
Valneva SE的股票代碼是VALN。
Valneva SE股票的52週最高點是多少？
Valneva SE股票的52週最高點是12.250。
Valneva SE股票的52週最低點是多少？
Valneva SE股票的52週最低點是4.021。
Valneva SE的市值是多少？
Valneva SE的市值是1.38B。
Valneva SE的淨利潤是多少？
Valneva SE的淨利潤為-12.25M。
現在Valneva SE(VALN)的股票是買入、持有還是賣出？
根據分析師評級，Valneva SE(VALN)的總體評級為買入，目標價格為12.887。
Valneva SE(VALN)股票的每股收益（EPS TTM）是多少
Valneva SE(VALN)股票的每股收益（EPS TTM）是-1.108。
相關品種
+0.41%
+0.94%
+0.51%
+0.34%
-0.17%
+1.42%
+0.75%
+1.80%
+0.38%
+0.66%
+0.08%
+0.82%
+0.81%
+0.08%
+0.23%
-0.05%
-0.19%
0.00%
+1.54%
+0.50%
